**We Claim:**

1. A method for treating a mammal suffering from a myocardial infarction comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor.

2. The method of claim 1 wherein the mammal is a human.

3. The method of claim 1 wherein the mammal is a non-human mammal.

4. The method of claim 1 wherein the Src family tyrosine kinase inhibitor is selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-*d*]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof.

5. The method of claim 1 wherein the Src family tyrosine kinase inhibitor is a pyrazolopyrimidine selected from the group consisting of 4-amino-5-(4-methylphenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*] pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(*t*-butyl) pyrazolo[3,4-*d*]pyrimidine, and a mixture thereof.

6. The method of claim 1 wherein the Src family tyrosine kinase inhibitor is a macrocyclic dienone selected from the group consisting of Geldanamycin, Herbimycin A, Radicicol R2146, and a mixture thereof.

7. The method of claim 1 wherein the Src family tyrosine kinase inhibitor is 6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanylphenylamino)-8*H*-pyrido[2,3-*d*]pyrimidine-7-one.

8. The method of claim 1 wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile.

9. The method of claim 8 wherein the 4-anilino-3-quinolinecarbonitrile has the general Formula (I):

(I)




wherein $R^1$ is methyl or $-(CH_2)_n-Z$; $X^1$ is F, Cl, Br, I, and methyl; $X^2$ is H, F, Cl, Br, I, and methyl; $X^3$ is H or methoxy; n is 2, 3, 4, or 5; and Z is 4-morpholinyl, 4-(1-methylpiperzinyl), 4-(1-ethylpiperzinyl), 4-(1-propylpiperzinyl), 1-(*cis*-3, 4, 5-trimethylpiperzinyl), 1-piperazinyl, 1-(4-methylhomopiperazinyl), 1-piperidinyl, 4-(1-hydroxypiperidinyl), 2-(1,2,3-triazolyl), 1-(1,2,3-triazolyl), 1-imidazolyl, $-NHCH_2CH_2$-1-morpholinyl, and $-N(CH_3)-CH_2CH_2-N(CH_3)_2$.

10. The method of claim 9 wherein $R^1$ is $-(CH_2)_n-Z$, wherein $X^1$ and $X^2$ are both chloro, $X^3$ is methoxy, n is 3 and Z is 4-morpholinyl.

11. The method of claim 8 wherein the 4-anilino-3-quinolinecarbonitrile is 4-anilino-3-quinolinecarbonitrile is 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile.

12. The method of claim 8 wherein the 4-anilino-3-quinolinecarbonitrile is 4-[(2,4-dichlorophenyl)amino]-6-methoxy-7-[3-(morpholin-4-yl)propoxy]-3-quinolinecarbonitrile (SKI-606).

13. The method of claim 1 wherein the pharmaceutical composition is administered to the mammal by intraperitoneal injection.

14. The method of claim 1 wherein the pharmaceutical composition is administered to the mammal by intravenous injection.

15. The method of claim 1 wherein the pharmaceutical composition is administered to the mammal within about 6 hours after the myocardial infarction.

16. The method of claim 1 wherein the pharmaceutical composition is administered to the mammal within about 24 hours after the myocardial infarction.

17. A method for treating a mammal suffering from a myocardial infarction comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising an ATP-competitive Src family tyrosine kinase inhibitor having a hydrophobic group that is less than about 6 angstroms in size situated adjacent to an ATP-mimicing heteroaromatic moiety.

18. The method of claim 17 wherein the ATP-competitive Src family tyrosine kinase inhibitor is a 5-(4-methylphenyl) substituted pyrazolo[3,4-*d*] pyrimidine compound.

19. The method of claim 17 wherein the ATP-competitive Src family tyrosine kinase inhibitor is a 5-(4-halophenyl) substituted pyrazolo[3,4-*d*] pyrimidine compound.

20. The method of claim 17 wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is a 4-(4-haloanilino)-3-quinolinecarbonitrile compound.

21. An article of manufacture comprising packaging material and a pharmaceutical composition contained within the packaging material, wherein the pharmaceutical composition is present in an amount capable of reducing necrosis in coronary tissue suffering from an impeded blood supply, the packaging material comprising a label which indicates that said pharmaceutical composition can be used for treatment of myocardial infarction, and wherein the pharmaceutical composition

comprises a chemical Src family tyrosine kinase inhibitor and a pharmaceutically acceptable carrier therefor.

22. The article of manufacture of claim 21 wherein the chemical Src family tyrosine kinase inhibitor is selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-*d*]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof.

23. The article of manufacture of claim 21 wherein the Src family tyrosine kinase inhibitor is a pyrazolopyrimidine selected from the group consisting of 4-amino-5-(4-methylphenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*-] pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(*t*-butyl) pyrazolo[3,4-*d*-]pyrimidine, and a mixture thereof.

24. The article of manufacture of claim 21 wherein the Src family tyrosine kinase inhibitor is a macrocyclic dienone selected from the group consisting of Geldanamycin, Herbimycin A, Radicicol R2146, and a mixture thereof.

25. The article of manufacture of claim 21 wherein the Src family tyrosine kinase inhibitor is 6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanyl phenylamino)-8*H*-pyrido[2,3-*d*]pyrimidine-7-one.

26. The article of manufacture of claim 21 wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile having the general Formula (I):

(I)



wherein $R^1$ is methyl or $-(CH_2)_n-Z$; $X^1$ is F, Cl, Br, I, and methyl; $X^2$ is H, F, Cl, Br, I, and methyl; $X^3$ is H or methoxy; n is 2, 3, 4, or 5; and Z is 4-morpholinyl, 4-(1-methylpiperzinyl), 4-(1-ethylpiperzinyl), 4-(1-propylpiperzinyl), 1-(*cis*-3, 4, 5-trimethylpiperzinyl), 1-piperazinyl, 1-(4-methylhomopiperazinyl), 1-piperidinyl, 4-(1-hydroxypiperidinyl), 2-(1,2,3-triazolyl), 1-(1,2,3-triazolyl), 1-imidazolyl, $-NHCH_2CH_2$-1-morpholinyl, and $-N(CH_3)-CH_2CH_2-N(CH_3)_2$.

27. The article of manufacture of claim 26 wherein $R^1$ is $-(CH_2)_n-Z$, wherein $X^1$ and $X^2$ are both chloro, $X^3$ is methoxy, n is 3 and Z is 4-morpholinyl.

28. The article of manufacture of claim 21 wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile selected from the group consisting of 4-anilino-3-quinolinecarbonitrile is 4-anilino-3-quinolinecarbonitrile is 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile and 4-[(2,4-dichlorophenyl)amino]-6-methoxy-7-[3-(morpholin-4-yl)propoxy]-3-quinolinecarbonitrile (SKI-606).

29. The article of manufacture of claim 21 wherein the Src family tyrosine kinase inhibitor is an ATP-competitive Src family tyrosine kinase inhibitor having a hydrophobic group that is less than about 6 angstroms in size situated adjacent to an ATP-mimicing heteroaromatic moiety.

30. A method for prophylactic treatment of a mammal at risk of myocardial infarction, the method comprising administering to the mammal a prophylactic amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor.

31. The method of claim 30 wherein the mammal is a non-human mammal.

32. The method of claim 30 wherein the mammal is a human.

33. The method of claim 30 wherein the pharmaceutical composition is orally administered to the mammal.

34. The method of claim 30 wherein the pharmaceutical composition is parenterally administered to the mammal.

35. The method of claim 30 wherein the chemical Src family tyrosine kinase inhibitor is selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-*d*]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof.

36. The method of claim 30 wherein the chemical Src family tyrosine kinase inhibitor is a pyrazolopyrimidine selected from the group consisting of 4-amino-5-(4-methylphenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*-] pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*-] pyrimidine, and a mixture thereof.

37. The method of claim 30 wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile having the general Formula (I):

(I)




wherein $R^1$ is methyl or $-(CH_2)_n-Z$; $X^1$ is F, Cl, Br, I, and methyl; $X^2$ is H, F, Cl, Br, I, and methyl; $X^3$ is H or methoxy; n is 2, 3, 4, or 5; and Z is 4-morpholinyl,

4-(1-methylpiperzinyl), 4-(1-ethylpiperzinyl), 4-(1-propylpiperzinyl), 1-(*cis*-3, 4, 5-trimethylpiperzinyl), 1-piperazinyl, 1-(4-methylhomopiperazinyl), 1-piperidinyl, 4-(1-hydroxypiperidinyl), 2-(1,2,3-triazolyl), 1-(1,2,3-triazolyl), 1-imidazolyl, $-NHCH_2CH_2$-1-morpholinyl, and $-N(CH_3)-CH_2CH_2-N(CH_3)_2$.

38. The method of claim 37 wherein $R^1$ is $-(CH_2)_n$-Z, wherein $X^1$ and $X^2$ are both chloro, $X^3$ is methoxy, n is 3 and Z is 4-morpholinyl.

39. The method of claim 30 wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile selected from the group consisting of 4-anilino-3-quinolinecarbonitrile is 4-anilino-3-quinolinecarbonitrile is 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile and 4-[(2,4-dichlorophenyl)amino]-6-methoxy-7-[3-(morpholin-4-yl)propoxy]-3-quinolinecarbonitrile (SKI-606).

40. The method of claim 30 wherein the Src family tyrosine kinase inhibitor is an ATP-competitive Src family tyrosine kinase inhibitor having a hydrophobic group that is less than about 6 angstroms in size situated adjacent to an ATP-mimicing heteroaromatic moiety.